19313-28-1

Basic information

• Product Name: 13,14-DIHYDROPROSTAGLANDIN E1
• Synonyms: 9-OXO-11ALPHA,15S-DIHYDROXY-PROSTAN-1-OIC ACID;13,14-DIHYDROPROSTAGLANDIN E1;PGE0;13,14-Dihydroprostaglandinee1;13,14-dihydro PGE1;7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoic acid;(11R)-11α,15α-Dihydroxy-9-oxoprostan-1-oic acid;13,14-Dihydro-prostaglandin E1 (PGE0)
• CAS NO: 19313-28-1
• Molecular Formula: C20H36O5
• Molecular Weight: 356.5
• Mol File: 19313-28-1.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 541.4°Cat760mmHg
• Flash Point: 295.3°C
• Appearance: /
• Density: 1.075g/cm³
• Vapor Pressure: 5.56E-14mmHg at 25°C
• Refractive Index: 1.499
• Storage Temp.: Refrigerator, under inert atmosphere
• Solubility: Ethyl Acetate, Methanol, Tetrahydrofuran
• Stability: Volatile
• CAS DataBase Reference: 13,14-DIHYDROPROSTAGLANDIN E1(CAS DataBase Reference)
• NIST Chemistry Reference: 13,14-DIHYDROPROSTAGLANDIN E1(19313-28-1)
• EPA Substance Registry System: 13,14-DIHYDROPROSTAGLANDIN E1(19313-28-1)

Safety Data

• Hazardous Substances Data: 19313-28-1(Hazardous Substances Data)

Usage

Description

13,14-DIHYDROPROSTAGLANDIN E1 (13,14-dihydro PGE1) is a biologically active metabolite of Prostaglandin E1 (PGE1) with comparable potency to the parent compound. It is characterized by its ability to inhibit ADP-induced platelet aggregation in human platelet-rich plasma (PRP) and washed platelets, making it a significant player in the realm of blood clotting and cardiovascular health. Additionally, 13,14-dihydro PGE1 has been shown to activate adenylate cyclase in NCB-20 hybrid cells, further contributing to its biological activities.

Uses

Used in Pharmaceutical Applications:
13,14-DIHYDROPROSTAGLANDIN E1 is used as a therapeutic agent for promoting cardiovascular health. Its ability to inhibit platelet aggregation makes it a valuable compound in the prevention and treatment of conditions related to blood clotting, such as thrombosis and atherosclerosis.
Used in Research Applications:
In the field of scientific research, 13,14-DIHYDROPROSTAGLANDIN E1 is used as a research tool to study the mechanisms underlying platelet aggregation and blood clotting. Its potent inhibitory effects on ADP-induced platelet aggregation make it a useful compound for investigating the roles of various signaling pathways and enzymes in these processes.
Used in Drug Development:
13,14-DIHYDROPROSTAGLANDIN E1 serves as a lead compound in the development of new drugs targeting blood clotting disorders. Its potent anti-aggregatory effects and activation of adenylate cyclase provide a foundation for designing novel therapeutics that can potentially offer improved efficacy and safety profiles compared to existing treatments.
Used in Diagnostic Applications:
13,14-DIHYDROPROSTAGLANDIN E1 can be employed in the development of diagnostic tests for assessing platelet function and blood clotting propensity. Its ability to inhibit platelet aggregation can be utilized to identify individuals at risk for developing thrombotic disorders or to monitor the effectiveness of antiplatelet therapies.

InChI:InChI=1/C20H36O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h15-17,19,21,23H,2-14H2,1H3,(H,24,25)/t15-,16+,17+,19+/m0/s1

Relevant articles and documents

A novel approach to the total synthesis of prostaglandins. Preparation of a stereoisomeric mixture containing (plus minus)-13, 14-dihydroprostaglandin E1 (1).

-